By Simon Ferdinand Eibach
Gdansk, May 6 (Reuters) – Swiss-American eye care company Alcon reported a 10% rise in its quarterly revenue, citing recent product launches as main drivers.
• Alcon’s net sales rose to $2.69 billion in the first quarter of 2026, from $2.45 reported a year earlier
• Sales missed $2.71 billion estimates by analysts polled by LSEG with net sales in the implantables segment almost stagnant due to competitive pressures
• Shares of Alcon opened down 4.67% at 0700 GMT with Vontobel analysts pointing to soft cataract markets
• Alcon’s operating earnings amounted to $292 million in the first quarter, falling 32% from a year earlier
• The company hiked its full-year guidance for diluted earnings per shares growth to 10%-13% from 9%-12% as it announced a $1.5 billion share repurchase program with a plan to cancel the acquired shares
• Alcon launched 10 new products in the first quarter of 2026, including Clareon TruPlus IOL, the next generation of monofocal and toric lenses for cataract surgery
(Reporting by Simon Ferdinand Eibach; Editing by Mrigank Dhaniwala)
